CN1091521A - 靶成分测定法 - Google Patents
靶成分测定法 Download PDFInfo
- Publication number
- CN1091521A CN1091521A CN93101332A CN93101332A CN1091521A CN 1091521 A CN1091521 A CN 1091521A CN 93101332 A CN93101332 A CN 93101332A CN 93101332 A CN93101332 A CN 93101332A CN 1091521 A CN1091521 A CN 1091521A
- Authority
- CN
- China
- Prior art keywords
- vesicle
- proportion
- antibody
- mixed liquor
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 title abstract description 3
- 239000002502 liposome Substances 0.000 claims abstract description 58
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 239000013060 biological fluid Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000012113 quantitative test Methods 0.000 claims description 13
- 210000003743 erythrocyte Anatomy 0.000 claims description 12
- 201000004792 malaria Diseases 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 2
- 241000223960 Plasmodium falciparum Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 210000002706 plastid Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 abstract description 2
- 230000005484 gravity Effects 0.000 abstract 2
- 239000000523 sample Substances 0.000 description 24
- 239000000975 dye Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000527 lymphocytic effect Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 4
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 4
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 238000004159 blood analysis Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 206010061548 Red blood cell abnormality Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84197692A | 1992-02-25 | 1992-02-25 | |
| US07/841,976 | 1992-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1091521A true CN1091521A (zh) | 1994-08-31 |
Family
ID=25286232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93101332A Pending CN1091521A (zh) | 1992-02-25 | 1993-02-24 | 靶成分测定法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5593848A (enExample) |
| EP (1) | EP0557595B1 (enExample) |
| JP (1) | JP2925105B2 (enExample) |
| CN (1) | CN1091521A (enExample) |
| AT (1) | ATE155889T1 (enExample) |
| AU (1) | AU662571B2 (enExample) |
| BR (1) | BR9300639A (enExample) |
| CA (1) | CA2090282A1 (enExample) |
| DE (1) | DE69221118T2 (enExample) |
| DK (1) | DK0557595T3 (enExample) |
| ES (1) | ES2106121T3 (enExample) |
| FI (1) | FI930821A7 (enExample) |
| GR (1) | GR3024970T3 (enExample) |
| MX (1) | MX9300965A (enExample) |
| NO (1) | NO930649L (enExample) |
| RU (1) | RU2116068C1 (enExample) |
| TW (1) | TW246716B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102788879A (zh) * | 2011-05-20 | 2012-11-21 | 常州康卫生物技术有限公司 | 一种生物检测试剂 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342790A (en) * | 1992-10-30 | 1994-08-30 | Becton Dickinson And Company | Apparatus for indirect fluorescent assay of blood samples |
| AU4101697A (en) * | 1996-11-22 | 1998-05-28 | Robert A. Levine | Process for enhancing the aggregation and/or agglutination of erythrocytes prior to centrifugation |
| AU9233698A (en) * | 1997-11-22 | 1999-06-17 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood |
| US6197523B1 (en) | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
| US6911315B2 (en) * | 1997-11-24 | 2005-06-28 | David L. Rimm | Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood |
| KR20010083070A (ko) * | 1998-06-26 | 2001-08-31 | 실버스타인 아써 에이. | 오메가-하이드록시 알데하이드와 아민과의 쉬프 염기부가물의 개선된 제조 방법 및 이를 기재로 하는 물질의조성물 |
| GB0021303D0 (en) * | 2000-08-30 | 2000-10-18 | Medinnova Sf | Use |
| EP1576126A3 (en) * | 2002-10-30 | 2005-10-26 | Pointilliste, Inc. | Systems for capture and analysis of biological particles and methods using the systems |
| WO2005016141A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US7996825B2 (en) * | 2003-10-31 | 2011-08-09 | Hewlett-Packard Development Company, L.P. | Cross-file inlining by using summaries and global worklist |
| WO2005067980A2 (en) * | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
| EP2274611B1 (en) | 2008-04-02 | 2013-06-05 | Abbott Point Of Care, Inc. | Self-calibrating gradient dilution in a constituent assay and gradient dilution apparatus performed in a thin film sample |
| WO2009126505A1 (en) * | 2008-04-09 | 2009-10-15 | Abbott Point Of Care, Inc. | Method of detecting very low levels of analyte within a thin film fluid sample contained in a thin thickness chamber |
| FR2965273B1 (fr) * | 2010-09-29 | 2015-07-17 | Centre Nat Rech Scient | Procede de preparation d'une structure chimique presentant une partition de phases, apte a generer un spectre de fluorescence specifique et ses applications |
| US9624474B2 (en) | 2010-12-01 | 2017-04-18 | Samsung Electronics Co, Ltd. | Method of separating target cell in biological sample |
| WO2016179530A1 (en) * | 2015-05-06 | 2016-11-10 | Seracare Life Sciences, Inc. | Liposomal preparations for non-invasive-prenatal or cancer screening |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862303A (en) * | 1972-02-02 | 1975-01-21 | Atomic Energy Commission | Method for rapid detection and identification of serological factors |
| US4027660A (en) * | 1976-04-02 | 1977-06-07 | Wardlaw Stephen C | Material layer volume determination |
| US4181609A (en) * | 1977-12-20 | 1980-01-01 | Levine Robert A | Blood constituents testing method |
| US4342739A (en) * | 1979-01-09 | 1982-08-03 | Fuji Photo Film Co., Ltd. | Novel material for immunological assay of biochemical components and a process for the determination of said components |
| US4332785A (en) * | 1980-04-09 | 1982-06-01 | University Patents, Inc. | Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein |
| IL64878A (en) * | 1982-01-27 | 1986-01-31 | Yissum Res Dev Co | Method for detection of and determination of malaria antibodies and malaria antigens in human blood |
| JPS5984162A (ja) * | 1982-11-05 | 1984-05-15 | Toshiba Corp | 免疫分析法 |
| US4591570A (en) * | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
| JPS6035267A (ja) * | 1983-08-05 | 1985-02-23 | Fuji Photo Film Co Ltd | 多項目免疫検査法 |
| US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| FR2571498B1 (fr) * | 1984-10-04 | 1988-04-08 | Immunotech Sa | Procede de separation de cellules utilisant des anticorps et des billes de faible densite |
| JPS6345563A (ja) * | 1986-04-11 | 1988-02-26 | Hitachi Ltd | 細胞分析方法 |
| US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
| GB2200448B (en) * | 1987-01-23 | 1991-01-16 | Univ London | Targetted liposomes and their use in immunoassay |
| US5017472A (en) * | 1987-09-09 | 1991-05-21 | Bankert Richard B | Microflotation devices used for immunoassays and cell/molecular fractionation |
| US4978625A (en) * | 1987-10-19 | 1990-12-18 | Becton, Dickinson And Company | Fluorescence immunoassay using water insoluble dyes |
| DE4041300A1 (de) * | 1989-12-22 | 1991-06-27 | Syntex Inc | Verfahren zur trennung von komponenten in einer mischung |
| JPH03249561A (ja) * | 1990-02-28 | 1991-11-07 | Toshiba Corp | 免疫分析試薬 |
-
1992
- 1992-12-01 AT AT92120505T patent/ATE155889T1/de active
- 1992-12-01 EP EP92120505A patent/EP0557595B1/en not_active Expired - Lifetime
- 1992-12-01 DK DK92120505.0T patent/DK0557595T3/da active
- 1992-12-01 DE DE69221118T patent/DE69221118T2/de not_active Expired - Fee Related
- 1992-12-01 ES ES92120505T patent/ES2106121T3/es not_active Expired - Lifetime
- 1992-12-02 AU AU29836/92A patent/AU662571B2/en not_active Ceased
-
1993
- 1993-02-19 BR BR9300639A patent/BR9300639A/pt not_active Application Discontinuation
- 1993-02-23 MX MX9300965A patent/MX9300965A/es unknown
- 1993-02-24 NO NO93930649A patent/NO930649L/no unknown
- 1993-02-24 JP JP5035368A patent/JP2925105B2/ja not_active Expired - Lifetime
- 1993-02-24 FI FI930821A patent/FI930821A7/fi unknown
- 1993-02-24 CA CA002090282A patent/CA2090282A1/en not_active Abandoned
- 1993-02-24 CN CN93101332A patent/CN1091521A/zh active Pending
- 1993-02-24 TW TW082101315A patent/TW246716B/zh active
- 1993-02-24 RU RU93004564A patent/RU2116068C1/ru active
-
1994
- 1994-11-07 US US08/335,310 patent/US5593848A/en not_active Expired - Fee Related
-
1997
- 1997-10-09 GR GR970402612T patent/GR3024970T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102788879A (zh) * | 2011-05-20 | 2012-11-21 | 常州康卫生物技术有限公司 | 一种生物检测试剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69221118T2 (de) | 1998-02-26 |
| EP0557595A2 (en) | 1993-09-01 |
| MX9300965A (es) | 1994-08-31 |
| AU662571B2 (en) | 1995-09-07 |
| FI930821A0 (fi) | 1993-02-24 |
| EP0557595A3 (enExample) | 1993-11-10 |
| TW246716B (enExample) | 1995-05-01 |
| NO930649L (no) | 1993-08-26 |
| EP0557595B1 (en) | 1997-07-23 |
| GR3024970T3 (en) | 1998-01-30 |
| BR9300639A (pt) | 1993-08-31 |
| CA2090282A1 (en) | 1993-08-26 |
| DK0557595T3 (da) | 1997-12-29 |
| DE69221118D1 (de) | 1997-09-04 |
| FI930821L (fi) | 1993-08-26 |
| RU2116068C1 (ru) | 1998-07-27 |
| ATE155889T1 (de) | 1997-08-15 |
| JP2925105B2 (ja) | 1999-07-28 |
| ES2106121T3 (es) | 1997-11-01 |
| AU2983692A (en) | 1993-08-26 |
| JPH0821833A (ja) | 1996-01-23 |
| FI930821A7 (fi) | 1993-08-26 |
| NO930649D0 (no) | 1993-02-24 |
| US5593848A (en) | 1997-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1091521A (zh) | 靶成分测定法 | |
| TW297094B (enExample) | ||
| US3915805A (en) | Quantitative detection of endotoxin in biological fluids | |
| KR940002520B1 (ko) | 고체-상 분석장치 및 분석방법 | |
| US5776711A (en) | Simultaneous human ABO and RH(D) blood typing or antibody screening by flow cytometry | |
| US4639419A (en) | Immunological color change test involving two differently colored reagent spots | |
| JPH01163662A (ja) | 抗原および／又は抗体の検出方法および検出用の試験キット | |
| EP0293779A1 (en) | Immunoassay making use of latex agglutination | |
| EP1059534A2 (en) | Simultaneous determination of forward and reverse ABO blood group | |
| KR880005458A (ko) | 생체내 세포추적 | |
| US4695553A (en) | Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample using antibodies | |
| US20120244630A1 (en) | Multiplexed analyte concentration measurement | |
| El Hoss et al. | A novel non-invasive method to measure splenic filtration function in humans | |
| JPH02296150A (ja) | 血液試験法 | |
| NO830732L (no) | Fremgangsmaate for detektering eller bestemmelse av histamin i histaminholdige materialer, spesielt legemsvaesker og et analytisk middel for bruk i en slik fremgangsmaate | |
| Price et al. | Disc electrophoresis on polyacrylamide gels of serum mucoids of individuals with selected chronic diseases | |
| CN1312477C (zh) | 不同阻抗系列免疫微球及制备方法、以及对其进行检测的方法与装置 | |
| Trudell | Detection and identification of antibodies | |
| JPS6281567A (ja) | 粒子凝集反応を用いる定量方法 | |
| CN107328941A (zh) | 一种可同时检测多种细胞粘附因子的抗体芯片 | |
| CN1209615C (zh) | 测定生物活性物质的目视荧光免疫分析法 | |
| JPS6281566A (ja) | 微粒子の螢光強度測定による定量方法 | |
| US3955923A (en) | Serologic reaction method | |
| JP3618797B2 (ja) | 免疫測定法 | |
| Hevessy et al. | Mean fluorescence intensity rate is a useful marker in the detection of paroxysmal nocturnal hemoglobinuria clones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |